Xbrane Biopharma (Q1 initial take): Soft Ximluci trajectory - Redeye

Xbrane's Q1 report showed a continued pressured outlook for Ximluci, with the volume growth in the quarter being negative. The company also disclosed changed deal-terms with its partner Intas, which improves the company's financial position but also signals continued balance sheet pressure.

Länk till analysen i sin helhet: https://www.redeye.se/research/1164058/xbrane-biopharma-q1-initial-take-soft-ximluci-trajectory?utm_source=finwire&utm_medium=RSS